

The authors reported no conflicts of interest.


The *Journal* policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest.

University of Toronto  
Toronto, Ontario, Canada

## References

1. Gomes WJ. Left main coronary artery stenosis: evidence and pathophysiology. *J Thorac Cardiovasc Surg.* 2020 [Epub ahead of print].
2. Gaudino M, Pagano D, Freemantle N. Commentary: the left main controversy: is this a real subgroup requiring bespoke clinical recommendations? *J Thorac Cardiovasc Surg.* April 15, 2020 [Epub ahead of print].
3. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, et al; ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease. *N Engl J Med.* 2020;382:1395-407.
4. Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Alexander KP, Senior R, et al; ISCHEMIA Research Group. Baseline characteristics and risk profiles of participants in the ISCHEMIA randomized clinical trial. *JAMA Cardiol.* 2019;4:273-86.
5. Bangalore S, Spertus JA, Stevens SR. Abstract #11656. Outcomes with Intermediate Left Main Disease on Coronary CT Angiography in the ISCHEMIA trial (ISCHEMIA Intermediate LM Substudy). Presented at: SCAI 2020 Scientific Sessions Virtual Conference; May 14-16, 2020.
6. Morice M-C, Serruys PW, Kappetein AP, Feldman TE, Stähle E, Colombo A, et al. Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. *Circulation.* 2014;129:2388-94.
7. Tajik P, Oude Rengerink K, Mol BW, Bossuyt PM. SYNTAX score II. *Lancet.* 2013;381:1899.
8. Neumann F-J, Sousa Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al; ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. *Eur Heart J.* 2018;34:2949.
9. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al; ACC/AHA Task Force Members, Society for Cardiovascular Angiography and Interventions, the Society of Thoracic Surgeons. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. *Circulation.* 2014;130:2354-94.
10. Tam DY, Bakaeen F, Feldman DN, Kolh P, Lanza GA, Ruel M, et al. Modality selection for the revascularization of left main disease. *Can J Cardiol.* 2019; 35:983-92.

<https://doi.org/10.1016/j.jtcvs.2020.06.034>



## REPLY: BEHIND ENEMY LINES: PRESERVING THE MYOCARDIUM SUPPLIED BY THE LEFT MAIN

Reply to the Editor:

In a recent letter, Gomes<sup>1</sup> discussed the concept that left main coronary artery (LMCA) stenosis is not a unique entity, but shares the same pathophysiologic characteristics as non-left main coronary artery disease (CAD). This hypothesis is also based on the recent evidence drawn from

the ISCHEMIA trial, in which invasive treatment of ischemia did not significantly affect survival relative to medical treatment alone.<sup>2</sup>

As Gomes<sup>1</sup> states, the prognosis of patients with CAD is mostly affected by acute coronary syndromes that occur as a result of rupture or erosion of non-flow limiting stenosis, rather than by the extent of ischemia. This justifies the hypothesis that LMCA stenosis is only a marker of diffuse CAD that might be associated with the presence of multiple unstable atherosclerotic plaques. It must be noted, however, that patients with LMCA stenosis were excluded from the ISCHEMIA trial, and its conclusions cannot be generalized.

In accordance with what has been elegantly discussed by Gaudino and colleagues,<sup>3</sup> LMCA should be considered a “clinical entity” in which the atherosclerosis process can involve not only the LMCA territory but also other coronary arteries. The clinical recommendation for the treatment of LMCA has historically treated LMCA disease as a unique “anatomic entity” rather than a “clinical entity,” because the LMCA supplies two-thirds of the myocardium (Figure 1).

In our recent meta-analysis, we found that percutaneous coronary intervention is associated with an increased risk of myocardial infarction at 5-year follow-up compared with CABG (odds ratio, 2.32; 95% confidence interval, 1.62-3.31;  $P < .001$ ) and with an increase in the number of repeat revascularizations (odds ratio, 1.89; 95% confidence interval, 1.58-2.26;  $P < .001$ ).<sup>4</sup> A subanalysis of the EXCEL trial showed that repeat revascularization was independently associated with increased risks for 3-year all-cause mortality and cardiovascular mortality and that most of the repeat revascularizations were the result of target lesion failure.<sup>5</sup> Our meta-analysis found no significant difference in all-cause mortality at 5 years.<sup>4</sup> None of the randomized clinical trials (including the EXCEL and NOBLE trials) were powered to assess mortality, but a pooled analysis of the EXCEL and NOBLE trials showed a survival benefit in the CABG group.<sup>3</sup>

Therefore, we would like to emphasize a “pathophysiologic concept”: LMCA stenosis as an anatomic entity puts a large amount of myocardium at risk and as a clinical entity is a marker of more extensive CAD. Acute myocardial infarction as a result of LMCA occlusion is a dramatic event because of the key anatomic role played by the LMCA in supplying the left ventricle.

The heart team’s mission should be to protect and save the myocardium. CABG, by achieving more complete revascularization and by protecting proximal segments of coronary arteries from the progression of the disease, is a valuable option in reducing the risk of repeat revascularization, myocardial infarction, and therefore mortality in patients with LMCA stenosis.

Michele Gallo, MD<sup>a</sup>  
Alvise Guariento, MD<sup>b</sup>  
Pietro L. Laforgia, MD<sup>c</sup>